Translational Development Acquisition Corp. (NASDAQ: TDAC) signed a subscription agreement for 5 million Class A shares at $10 each, delivering $50 million of cash and an equal number of warrants. The infusion strengthens the company’s balance sheet and aligns financing with the upcoming merger, offering investors a defined path to ProLogium equity and upside from the warrants.

Key Highlights

  • TDAC will sell 5,000,000 Class A ordinary shares at $10.00 per share, raising $50,000,000 in total.
  • The same number of warrants will be issued, each exercisable at $11.50 per share with a redemption trigger at $18.00.
  • Shares trade at a level above the subscription price, reflecting market interest in the upcoming transaction.

Translational Development Acquisition Corp. (NASDAQ: TDAC) has executed a subscription agreement that will generate $50 million by selling 5 million of its Class A ordinary shares at $10.00 per share. In return, the investor will obtain a matching 5 million warrants, thereby expanding the company’s capital base shortly before the anticipated merger with ProLogium is slated to close. This financing step adds a significant cash reserve and aligns the capital structure with the forthcoming share exchange, where each subscribed share will be cancelled for a ProLogium Class A share.

The move demonstrates the company’s preparedness to consummate the merger and offers investors a straightforward path to convert their holdings into ProLogium equity.

Subscription Mechanics and Warrant Terms

Under the agreement the subscriber will deliver the full $50 million into escrow prior to the subscription closing, which is scheduled one business day before the first merger. No downward reset, ratchet, or additional protective features are attached, aside from standard anti‑dilution adjustments. Upon completion of the merger, each subscribed share will be cancelled and exchanged for one ProLogium Class A ordinary share with a par value of $0.0001, while any outstanding warrants will convert into ProLogium warrants on comparable terms.

The alignment of share and warrant quantities simplifies the capital transition and limits dilution for existing shareholders.

Market Context and Immediate Impact

The infusion of $50 million at a $10.00 per share price strengthens liquidity and supports the company’s strategic objectives ahead of the merger. Investors now have the option to exercise warrants at $11.50 per share, providing a defined upside relative to the subscription price, while the redemption trigger at $18.00 offers a ceiling for downside risk in a volatile environment. This structure may appeal to participants seeking exposure to the ProLogium combination while mitigating immediate price pressure.

Forward Catalyst: Merger Timing and Registration Deadline

The subscription closing is set to occur one business day before the first merger, which is expected to be finalized shortly after the end of July. ProLogium has committed to filing a resale registration statement for the shares and warrants received from this transaction within the applicable statutory period following the merger. Investors should monitor the effectiveness of the Form F‑4 related to the merger, as that event will trigger the conversion of subscribed shares into ProLogium equity and activate the warrants. The timing of that filing, together with the redemption trigger at $18.00, will shape near‑term liquidity and valuation dynamics for TDAC shareholders.

Analysis based on the Form 8-K filed 27 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.